Trial reportEuropean journal of nuclear medicine and molecular imaging2019
Biodistribution and radiation dose estimates for
Trial report in European journal of nuclear medicine and molecular imaging, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 1 synthesis or guideline pooled it, 58 citations in OpenAlex.
- Theranostic Radiopharmaceuticals of Somatostatin Receptors for Patients with Neuroendocrine Tumors: Agonists Versus Antagonists-A Systematic Review and Meta-Analysis.International journal of molecular sciences · 2025Pooled it
- A Prospective, Randomized, Double-Blind Study to Evaluate the Safety, Biodistribution, and Dosimetry ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Trial
- Comparison ofEuropean journal of nuclear medicine and molecular imaging · 2020Trial
- Head-to-head comparison of [European journal of nuclear medicine and molecular imaging · 2026Article
- Gallium-Containing Agents for Tumor Diagnosis and Therapy: Current Status and Future Prospects.Small (Weinheim an der Bergstrasse, Germany) · 2026Review
- Synthesis, preclinical evaluation, and clinical translation of [European journal of nuclear medicine and molecular imaging · 2026Article
- Comparison of radiolabeled somatostatin analogs (DOTATATE, DOTANOC, and DOTATOC) in somatostatin receptor (SSTR) imaging for gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs): a narrative literature review.Annals of nuclear medicine · 2025Review
- Review
- Emerging innovations in theranostics for pancreatic neuroendocrine tumors.NPJ precision oncology · 2025Review
- Targeted radionuclide therapy and diagnostic imaging of SSTR positive neuroendocrine tumors: a clinical update in the new decade.Frontiers in nuclear medicine · 2025Review
- First-in-human study of an optimized, potential kit-type, SSTR antagonistTheranostics · 2025Article
- Limitations of the radiotheranostic concept in neuroendocrine tumors due to lineage-dependent somatostatin receptor expression on hematopoietic stem and progenitor cells.Theranostics · 2025Article
- Gallium-68 labeled somatostatin receptor antagonist PET/CT in over 500 patients with neuroendocrine neoplasms: experience from a single center in China.European journal of nuclear medicine and molecular imaging · 2024Article
- Theranostics - a sure cure for cancer after 100 years?Theranostics · 2024Review
- Inspired by novel radiopharmaceuticals: Rush hour of nuclear medicine.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2023Article
- Next-generation PET/CT imaging in meningioma-first clinical experiences using the novel SSTR-targeting peptide [European journal of nuclear medicine and molecular imaging · 2023Article
- Nuclear Medicine and Radiological Imaging of Pancreatic Neuroendocrine Neoplasms: A Multidisciplinary Update.Journal of clinical medicine · 2022Review
- Emerging Nuclear Medicine Imaging of Atherosclerotic Plaque Formation.Journal of imaging · 2022Review
- Diagnostic Value of Radiolabelled Somatostatin Analogues for Neuroendocrine Tumour Diagnosis: The Benefits and Drawbacks of [Cancers · 2022Review
- Radiolabeled Somatostatin Analogs-A Continuously Evolving Class of Radiopharmaceuticals.Cancers · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 2 countries.
Funding
Abstract
purposeSomatostatin receptor antagonists have shown promise for imaging neuroendocrine tumors (NETs) in preclinical studies, but clinical data is still very limited. In this study, we assess the feasibility of using the novel somatostatin antagonist
methodsTwenty patients with advanced NETs underwent whole-body PET/CT imaging 60 min after injection of 169 MBq (median)
resultsIn contrast to the known biodistribution of somatostatin receptor agonists, little or no uptake above background was seen in the pituitary gland, spleen, adrenals, and uninvolved liver; e.g., median spleen SUV
conclusions
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.